A Phase 1 interventional study of Ketamine (0.25 mg/kg) and Ketamine (0.5 mg/kg) in Treatment Resistant Depression (TRD), sponsored by Soterix Medical. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Soterix Medical · Phase 1, Interventional, and Treatment
Funding was not provided
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant — 8 open to participants now, 11 under way, 3 of them phase 3. Ketamine · Depressive Disorder, Treatment-Resistant.
Among the 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant, this one is the 40th largest by enrollment, is one of 3 that started in 2025, is one of 7 in phase 1, and was the 40th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →8 of the 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant are open now, in 8 countries. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18–70
Joshua Rosenblat · Sites in Canada
Ages 18–70
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–70
Mayo Clinic · Sites in United States
Ages 18–65
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 8 · Phase 4 8
First in 2008; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 35 across the 42 interventional studies. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 42 have an industry lead sponsor. The 10 most frequent:
Soterix Medical is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Soterix Medical has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
3 of the studies testing ketamine in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT06480201Texas A&M UniversityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | 2026-12-31 |
| NCT06480500University Health Network, Torontoi-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
This trial is a biomarker development study. The effects of various doses of ketamine infusion on depressive symptoms and EEG signals in patients with unipolar depression will be analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.25 mg/kg ketamine infusion
Drug: Ketamine (0.25 mg/kg)
0.5 mg/kg ketamine infusion
Drug: Ketamine (0.5 mg/kg)
0.75 mg/kg ketamine infusion
Drug: Ketamine (0.75 mg/kg)
Hamilton Depression Rating Scale (HDRS) 22
Twenty-two question Depression rating scale (excluding the two questions on weight loss and diurnal variation)
Time frame: Baseline, Hour 1, Hour 4, Hour 24, and Hour 72
The Columbia Suicidality Severity Rating Scale (C-SSRS)
A semi-structured, investigator-rated interview assessing both suicidal behavior and suicidal ideation.
Time frame: Baseline, Hour 1, Hour 4, Hour 24, and Hour 72
The Clinician Administered Dissociative States Scale (CADSS)
A scale that rates dissociative symptoms with a 27-item scale, rated 0-4, 19 subjective, and 8 observer items
Time frame: Baseline, and Hour 1
Montgomery-Asberg Depression Rating Scale (MADRS)
A ten-item diagnostic used for the assessment of depression severity
Time frame: Baseline and Hour 24
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2027, 23 months later.
How these figures are worked out, and which studies are left out of them.
Funding was not provided
Funding was not provided
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine
Depressive Disorder, Treatment-Resistant →
Soterix Medical